Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REP 2139-Mg + peginterferon alfa-2a + tenofovir disoproxil fumarate
- Development stage
- Phase 2
- Lead developer
- Replicor
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
This drug is a combination therapy consisting of REP 2139-Mg (a magnesium chelate nucleic acid polymer), peginterferon alfa-2a (a pegylated form of recombinant human interferon alfa-2a), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor). REP 2139-Mg is designed to clear hepatitis B virus surface antigen (HBsAg), which enables restoration of immune control over HBV and HDV infections. Peginterferon alfa-2a acts as an immunomodulatory cytokine that upregulates interferon-stimulated genes and bolsters antiviral immune responses. Tenofovir disoproxil fumarate inhibits viral reverse transcriptase, limiting replication of hepatitis B virus. This triple combination is primarily being investigated for the treatment of chronic hepatitis B and hepatitis D (HDV) infections, particularly in patients with cirrhosis and those unresponsive to other therapies[8][4][1].
- Other names
- peginterferon alpha-2atenofovirTDF
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on REP 2139-Mg + peginterferon alfa-2a + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REP 2139-Mg + peginterferon alfa-2a + tenofovir disoproxil fumarate.